Artivion (NYSE:AORT) Insider John Davis Sells 6,394 Shares

Artivion, Inc. (NYSE:AORT) insider John Davis sold 6,394 shares of Artivion stock in a transaction on Monday, November 17th. The stock was sold at an average price of $45.17, for a total transaction of $288,816.98. Following the completion of the transaction, the insider directly owned 198,842 shares in the company, valued at approximately $8,981,693.14. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artivion Trading Up 0.7%

Shares of AORT stock traded up $0.32 during trading hours on Tuesday, reaching $45.44. The company’s stock had a trading volume of 149,362 shares, compared to its average volume of 433,748. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.04. The stock has a market capitalization of $2.15 billion, a P/E ratio of -108.26 and a beta of 1.65. The firm’s fifty day simple moving average is $42.72 and its 200 day simple moving average is $36.51.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. The company’s revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Artivion by 8.3% in the third quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after acquiring an additional 232,424 shares during the period. Wellington Management Group LLP increased its position in shares of Artivion by 4.1% during the 1st quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company’s stock valued at $42,460,000 after purchasing an additional 67,327 shares during the last quarter. Next Century Growth Investors LLC lifted its stake in shares of Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock worth $25,140,000 after purchasing an additional 530,122 shares during the period. Bank of America Corp DE boosted its holdings in shares of Artivion by 22.8% in the second quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after buying an additional 119,634 shares during the last quarter. Finally, Invesco Ltd. grew its position in Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after buying an additional 139,370 shares during the period. Institutional investors own 86.37% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Citizens Jmp lifted their price target on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Canaccord Genuity Group raised their price objective on Artivion from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, November 7th. JMP Securities increased their target price on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. Citigroup restated an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Finally, Stifel Nicolaus increased their price objective on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.